On the back of fine-grained readouts from a battery of late-stage tests, Eli Lilly now has its once-a-week insulin play, efsitora alfa, on tap in the hunt for regulatory approval.
Lilly gave a detailed description of the positive outcomes at its annals that had been carried out in the QWINT-2, QWINT-3 and QWINT-4 studies involving the efsitora in patients with Type 2 diabetes over first-time insulin, previous users of daily basal insulin, and previous users of daily basal insulin and mealtime insulin, respectively.
The candidate, Efsitora, which would enable patients with diabetes to reduce the number of insulin types injections to more than 300 fewer injections each year, if authorized, assisted patients in the achievement of noninferiority in blood sugar reduction during A1C (blood sugar) across all three research studies, thus enabling the clutch of trials to record their key goals, Lilly said.
Having achieved those winning results, Lilly says that it now intends to introduce its efsitora data package to world regulatory agencies by the end of the year. On the whole, Lilly has announced positive readouts in five trials of the QWINT program, which has already started in 2022.
The efsitora momentum is receiving a boost as Novo Nordisk, the chief competitor in the metabolic medicines business to Lilly, has not been able to achieve approval in the U.S. of its weekly insulin product. That notwithstanding, the drug that Novo markets under the name of Awiqli has already received authorizations in places such as Europe, Canada, Japan, and Australia.
Disaggregating the outcomes, Efsitora aided in lowering the A1C of patients by 1.31 per cent compared to 1.27 per cent of insulin glargine at week 52 of QWINT-1 trial. In QWINT-3, efsitora lowered A1C by 0.86% at Week 26 and 1.07% in QWINT-4 by the same time compared to 0.75% in insulin degludec and 1.07% in insulin glargine.
Lilly has also presented the outcomes of some important secondary endpoints of QWINT-3 and 4. In the former trial, glucose levels of the efsitora patients were in range 62.8 percent of the total four weeks before Week 26 of the trial investigation, whereas those taking insulin degludec did so 61.3 percent of the time.
In QWINT-4, where efsitora was effective in assisting 39.5 percent of patients in the achievement of an A1C less than 7 percent at week 26 without nocturnal hypoglycemia, when compared with 36.6 percent of patients who take insulin glargine.
In the case of QWINT-1, Lilly states that it titrated efsitora to four constant doses at intervals of four weeks, as it was required to control blood glucose. The company gave efsitora in the form of traditional insulin dosing and manipulation by the glucose level of the patients at QWINT-3 and QWINT-4 trials.
Efsitora was non-inferior in its safety to insulin glargine and insulin degludec, which are among the most widely used doses per day of basal insulin, Lilly said in its release.
QWINT-1 study Patients on efsitora recorded about a 40 percent reduction in hypoglycemia events, or the occurrence of an abnormal fall in the level of sugar in the blood, compared to insulin glargine, Lilly noted.
In the meantime, at 52 weeks of the QWINT-1 study, the approximate probability of combined incidence of severe or clinically significant hypoglycemic events per patient-year of exposure was 0.50 in the efsitora group and 0.88 in the insulin glargine group. In the case of QWINT-3, the results were 0.84 in the case of efsitora and 0.74 in the case of insulin degludec at a 78-week mark, whereas QWINT-4 results in the case of efsitora were 6.6 and in the case of insulin glargine, 5.9 at a 26-week mark.
In the entire QWINT program, Lilly has examined the work of efsitora on over 3,000 patients with Type 2 diabetes. QWINT-1 had the number of participants 795 in comparison with 986 in QWINT-3 and 730 in QWINT-4.
At the 85th American Diabetes Association Scientific Sessions in Chicago, Lilly announced the most recent three readouts. According to Lilly, the QWINT-1 outcomes were published in The New England Journal of Medicine, and the QWINT-3 and 4 data found their way to The Lancet.
The closely watched QWINT-1, 3, and 4 represent a continuation of favorable reads of the program since last May, when Lilly first announced that both the QWINT-2 and 4 trials had achieved their respective nontoxicity endpoints of A1C. The QWINT-2 was especially aimed at determining whether or not the administration of the GLP-1 drugs in diabetes, such as Mounjaro or Ozempic, may burden the performance of efsitora.
Lilly is making a huge bet that Efsitora will be able to benefit not only current patients with daily insulin treatment but also get the new patients to start taking the drug.
It has the potential of 313 fewer injections a year, considering it as an insulin drug, Paul Owens, VP of global brand development, insulins and glucagon, in an interview last year. We hope that it will be used to enhance adherence … and the innovation of a single, once-weekly dosing regime could make the whole difference between initiating the treatment or not in some individuals.”
Patients with diabetes have spent almost the last century struggling with daily doses of insulin, and those recurring shots as a reaction to the blood glucose checks can be a burden to those, according to Owens, at that point.
Since Novo Nordisk was the first company to launch a weekly insulin product, Awiqli, in other markets, it looked as though Lilly would trail behind in the competition in the United States.
In July of last year, the FDA had denied the Novo request for the product, which would also go by the name of insulin icodec. Novo blamed the rejection on the requests arising in relation to the manufacturing process and type 1 diabetes indication. Back then, Novo warned that it would not have such an issue solved by the end of 2024.
The snub came after an FDA advisory committee delivered an unfavorable ruling, much of which involved the issue of the possible potential of icodec to cause low blood sugar.
In the end, 7 out of 11 panelists approved a statement claiming that the data provided by Novo were not adequate to draw a conclusion regarding icodec being a substance that has more advantages than risks in adults with Type 1 diabetes.
